相关实验视频

Updated: Jul 7, 2026

NMR-Based Activity Assays for Determining Compound Inhibition, IC50 Values, Artifactual Activity, and Whole-Cell Activity of Nucleoside Ribohydrolases
10:24

NMR-Based Activity Assays for Determining Compound Inhibition, IC50 Values, Artifactual Activity, and Whole-Cell Activity of Nucleoside Ribohydrolases

Published on: June 30, 2019

10.1K

评估N-89作为口服抗疟疾药物的活性

Nagwa S M Aly1,2, Hiroaki Matsumori1, Thi Quyen Dinh1

  • 1Department of International Infectious Diseases Control, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama 700-8530, Japan.

Parasites, hosts and diseases
|August 30, 2023
PubMed
概括

这种新型化合物1,2,6,7-tetraoxaspiro[7.11]nonadecane (N-89) 在小鼠中显示出有前途的口服抗疟疾活性,对抗Plasmodium berghei. N-89有效地消除了疟疾寄生虫,并实现了治愈,因此需要对疟疾治疗进行进一步研究.

关键词:
新的抗疟疾候选药物在活体中,活体中在口服中使用N-89药物动力学 药物动力学

更多相关视频

Optimized Griess Reaction for UV-Vis and Naked-eye Determination of Anti-malarial Primaquine08:31

Optimized Griess Reaction for UV-Vis and Naked-eye Determination of Anti-malarial Primaquine

Published on: October 11, 2019

10.3K
Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

1.2K

相关概念视频

Anthelminthic Agents01:15

Anthelminthic Agents

Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
Antiprotozoal Agents01:21

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...